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ABSTRACT
The mission of the PharmaSat biological microsatellite is to investigate the efficacy of anti-fungal agents in the
spaceflight environment. The satellite uses autonomous, in situ bio-analytical and sample management technologies
in order to culture and characterize the growth of multiple samples of yeast, which are exposed to differing levels of
an anti-fungal agent during their growth cycle. The satellite uses a 10 cm x 10 cm x 30 cm Cubesat-class structure
with body-mounted solar panels, an ISM-band transceiver, and a simple PIC-class microcontroller for the main
flight computer. PharmaSat was launched on May 19, 2009 from Wallops Flight Facility as a secondary payload on
a Minotaur launch vehicle. During the first week of operation, the primary biological experiment was conducted,
and data from this experiment was downloaded thereby achieving mission success. The PharmaSat design and
mission control architecture inherits many features and design strategies from the GeneSat-1 mission, which was
previously developed by the same design group at NASA Ames Research Center and Santa Clara University. This
paper presents the PharmaSat mission, the design of its spacecraft and ground segment, and initial flight results.
limited. Much of it has been done in microgravity
simulators on the ground, which do not have perfect
fidelity. Experiments in space have been time-limited
and don’t approach the durations that humans would be
exposed to during planetary missions. Furthermore, the
sheer numbers of samples over which these studies
have been conducted have been limited, given the need
to conduct clinical biological trials on a statistical basis.

INTRODUCTION
NASA’s combined interests in astrobiology and in
developing capabilities to support long-duration human
spaceflight require a deep understanding of the effects
of the space environment on biological systems.
For human spaceflight, preliminary findings in three
complementary areas demonstrate the inherent
challenges:
1. Space
flight
causes
immunosuppression,
presumably due to microgravity environment
stressors, thereby increasing infection risk for
astronauts;1,2,3,4
2. Some pathogens, such as the bacteria Salmonella,
become more virulent in a microgravity
environment;1,5,6,7 and
3. Some pathogens have developed increased drug
resistance in a microgravity environment.1,8

In terrestrial medical research, many advances in
therapeutics have resulted from a detailed
understanding of biological mechanisms and pathways
at the molecular level.9
Accordingly, there is
significant interest within NASA to provide
experimental capabilities within the microgravity
environment in order to provide a similar level of
insight. Work of this type has been conducted on the
Space Shuttle and the International Space Station;1,5
however, such experiments can be costly (particularly
due to the involvement of crew members), require a
significant amount of time to coordinate, and can yield
less-than-true microgravity levels due to induced
vibrations caused by crew and support systems
operation.10

This establishes a trifecta of challenges for human
spaceflight in that humans are more susceptible to
illness, the germs are more potent, and the drugs that an
astronaut might take are less effective. The research
supporting these observations, however, has been
Kitts
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Shown in Figure 1, the GeneSat-1 spacecraft used a
triple Cubesat form factor with an additional cylindrical
extension on one end to house an amateur radio beacon
in support of the mission’s outreach program. The
satellite bus included four body-mounted solar panels, a
single battery, a PIC-based command and data handling
board, a passive magnet/hysteresis rod orientation
control suite, a 2.4 GHz ISM communication
transceiver, and the amateur radio beacon.
A
pressurized, sealed cylinder housing the biological
experiment held a fluidic card containing twelve
samples of E. coli and support equipment designed to
incubate and characterize the biology over the course of
a 96-hour experiment. This support equipment included
an integrated micro fluidics network, temperature
control components, and the optical sensors.13

Small Spacecraft for Biological Research
The hypothesis of the Small Spacecraft Division at
NASA Ames Research Center is that cost-effective
microgravity research can be achieved with small
spacecraft with the level of high-quality performance
required to inform the fundamental biological questions
of interest. Apart from the normal challenges involved
in the development of low-cost small spacecraft, using
such vehicles for biological research offers its own set
of challenges. These include the need to store, feed,
and culture biological samples while providing critical
life support functions and performing in situ
experimental measurements with a high level of
fidelity.
The Ames Small Spacecraft Division is involved with a
developing the biological payload technology that will
enable this vision for nanosat-sized spacecraft, with an
initial focus on sub-5 kg spacecraft in a 10 cm x 10 cm
x 30 cm triple Cubesat form factor. This work requires
miniaturization of the tools, methods, and liquid
volumes of modern molecular biology, as well as the
sensors, electronics, and automated processing
necessary to implement sophisticated analytical
measurement systems.

All primary science and engineering test objectives
were completed successfully within one month of
operation. Since that time, additional trend analyses and
experiments have been performed to further quantify
the performance of the bus. In addition, the satellite has
been the focal point of a highly successful university
and amateur radio community program that includes its
use in a satellite operation class, for student-led
engineering research, and as a focal point for a robust
K-12 outreach program.

GeneSat-1

PreSat and NanoSail-D

The GeneSat-1 mission was the first Ames mission to
explore the use of small spacecraft supporting a
miniaturized in situ payload for biological
experimentation. Launched in December 2006 from
Wallops Flight Facility as a secondary payload on a
Minotaur launch vehicle, GeneSat-1 performed an
experiment investigating the affect of microgravity on
the metabolism of E. coli.
While providing
scientifically interesting results, the primary value of
the mission was to validate the developed research
grade instrumentation.11,12

While developing PharmaSat, the Ames team was given
an opportunity to launch an early engineering prototype
on a Summer 2008 launch from Kwajalein Atoll onboard the 3rd flight of a SpaceX Falcon 1 rocket. This
prototype, nicknamed PreSat, was intended to qualify
key aspects of the PharmaSat design, to include the
instrumentation, the microfluidic system, and the
thermal control system. It was also an operational test
for the team to operate at a new launch site, to integrate
with a new corporate partner, and to demonstrate
rapidly developed portable communication stations
deployed at low-latitude locations (Kwajalein and El
Salvador) as appropriate for the projected lowinclination orbit.14
Unfortunately, the SpaceX rocket suffered from an
anomaly which prevented PreSat from achieving orbit.
Also lost on the same flight was NanoSail-D, another
triple cube spacecraft developed to demonstrate
solar/drag sail technology and developed by Ames and
NASA Marshall Space Flight Center. Although the
flight opportunity was lost, development of these
vehicles provided the Ames team with the opportunity
to mature their development and management processes
to support low-cost, rapidly developed small satellite
missions.

Figure 1: The GeneSat-1 Space System
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2.

THE PHARMASAT MISSION
The NASA PharmaSat mission focuses on the third
element of the previously described human spaceflight
challenge by measuring the influence of microgravity
on yeast resistance to an antifungal agent. Results are
intended to inform the development of countermeasures
for this effect, applicable to long-term human
spaceflight and habitation.

3.
4.
5.

In conducting this mission, the PharmaSat team has set
a precedent as being the first competitively selected,
peer-reviewed, science-driven mission to use a
spacecraft under the 10 kg mass threshold.
Furthermore, mission development was conducted
using industry-standard project management and
systems engineering processes as specified by NASA
Procedural Requirement 7120.5E.

Dose independent subsets of the growing yeast
samples with three distinct, well-defined dosage
levels of an antifungal agent, with an extra subset
subjected to a zero-dose control,
Track the population of the yeast by measuring the
optical density of each microwell before, during
and after antifungal administration,
Determine well-by-well yeast viability at multiple,
well-defined times after antifungal administration
using a colorimetric reagent, Alamar Blue, and
Telemeter the resulting population and viability
data to Earth, along with system status data.

To achieve this, the PharmaSat space system borrowed
heavily from GeneSat-1, reusing key elements of the
satellite bus as well as a significant portion of the
ground segment.
THE PHARMASAT SPACE SYSTEM

To achieve its drug efficacy experiment, the PharmaSat
system was designed to accomplish five critical
functions:
1. Provide life support and environmental control for
growth of the yeast strain in 48 independent
microwells,

As shown in Figure 2, the PharmaSat space system
consists of the PharmaSat spacecraft, several
communication stations, and a variety of Mission
Control Node locations for conducting realtime
command and telemetry operations.

Figure 2: The PharmaSat Space System
Kitts
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PharmaSat Spacecraft
The design of the PharmaSat spacecraft significantly
leveraged previous work with GeneSat-1.
The
spacecraft is constructed from off-the-shelf commercial
and NASA-designed parts in order to implement a selfcontained, automated space science laboratory. The
spacecraft, pictured in Figure 3, consists of a bus
module (1 CubeSat volume) and a payload module (2
CubeSat volumes). The entire satellite, depicted in
Figure 2, is approximately 100mm x 100mm x 340mm
and weighs under 5 kg. The satellite bus includes
body-mounted solar panels, a single battery, a PICbased command and data handling board, a passive
magnet/hysteresis rod orientation control suite, a 2.4
GHz Microhard communications transceiver, and an
amateur radio beacon.

Figure 3: The PharmaSat Satellite

The PharmaSat payload is contained in a pressurized,
sealed cylinder; the payload module and its gold
pressure vessel are pictured in Figure 4. Included in
this module are:
• A 4 in x 8 in plastic microwell plate, shown in
Figure 5, which accommodates 48 fluidic
microwells in which yeast samples are cultured,
• A microfluidics system of tubes, pumps, and valves
that provide sugars to the yeast for food and which
dose them with the antifungal agent,
• An optical sensor system to detect the health and
size of the yeast populations, and
• A miniaturized environmental control and power
control system.

Figure 4: The GeneSat-1 Payload Module

A cross section depiction of the microwell plate is
shown in Figure 6. Cells are contained within the wells
by nylon filters. Permeable membranes on both sides
of the wells allow for adequate gas exchange between
the wells and the payload environment.
Yeast cells were transferred to a stasis buffer and
loaded into the microwell plate in a lab environment six
weeks prior to the nominal launch date. About 2 days
after launch, once the satellite was shown to be healthy
and a microgravity environment had been established,
the experiment was initiated by raising the plate
temperature to 27°C and feeding the cells with growth
media that contained Alamar Blue. The cells were then
allowed to grow for approximately 10.4 hours in order
to recover from stasis. Then, each of the four well
subsets was “challenged” with a different concentration
of the antifungal agent voriconazole (one of which had
none, as an experimental control). By observing the
colorimetric change in the Alamar Blue (which is a
function of cell metabolic activity), instruments
measured growth and viability at 15-minute intervals
over a period of 72 hours.
Kitts
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Figure 6: Microwell Plate Cross-Section12
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Launch Adaptor
The Cal Poly Picosatellite Orbital Developers (P-POD)
is a simple device designed to release picosatellites into
space. Shown in Figure 7 during launch vehicle
integration, the P-POD mounts to the launch vehicle,
encapsulates the picosatellites during launch in order to
protect primary payloads, and ejects the picosatellites
upon receipt of a simple trigger signal. The body of the
P-POD is an aluminum box with a spring-loaded
plunger that acts like a jack-in-the-box to push one or
more CubeSat-class satellites out of the box once the
door opens.15
Figure 7: P-POD Fit Check

The standard P-POD design was delivered by the Cal
Poly team and then, as with the P-POD used for
GeneSat-1, modified by NASA Ames in order to
accommodate a custom structural configuration used on
the PharmaSat vehicle. As seen in Figure 3, a
cylindrical extension was made to one end of the
satellite in order to accommodate an amateur radio
beacon in support of the mission’s education/outreach
program.
Because of the limited volume, this
equipment was placed outside of the standard CubeSat
form factor. The cylindrical projection was configured
to fit within the P-POD’s helical ejection spring; in
supporting this, modifications to the P-POD pusher
plate assembly were made.

Figure 8: SRI and SCU Communication Stations

The second P-POD modification was the installation of
an NEA release mechanism for opening the door; this
was motivated due to thermal loading concerns in the
launch environment.
Communications Stations
PharmaSat’s primary command and telemetry
communications are supported through a 2.4 GHz SBand link using a COTS transceiver, the Microhard
MHX-2400. This same transceiver was used on
GeneSat-1, and its performance has been characterized
in detail by the mission operations team.16

Figure 9: Communication Station Diagram
Reception of PharmaSat’s UHF amateur radio beacon is
possible through a number of station configurations.
An OSCAR station configuration is typical, and
consists of a steerable Yagi antenna, a standard
satellite-compatible
transceiver
with
Doppler
compensation, and a packet modem. The SCU OSCAR
antenna rig is shown in Figure 8, and the SRI antenna is
equipped with a dual-frequency feed that allows it to
simultaneously support 2-way S-Band operations and
receive-only beacon reception. The team has also
demonstrated beacon reception using simple hand-held
antennae.

The primary communication station was a facility
leased from SRI in Palo Alto, CA which had previously
been refurbished and continues to be used by the
GeneSat-1 team. This facility has a high-gain 18-meter
antenna capable of 0.1° pointing accuracy and a
maximum azimuth rate of approximately 5 °/sec. Two
additional S-Band stations at Santa Clara University in
Santa Clara, CA, were also used for conducting
command and telemetry operations. These duplicate
stations use a 3-meter antenna and have a pointing
accuracy of 0.5° and a maximum azimuth rate of
approximately 6 °/sec. The antennae for both facilities
are shown in Figure 8.
Kitts
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workstations, power control equipment, and an
independent antenna-tracking console. Figure 9 depicts
a component block diagram for the stations; this
configuration is nearly identical for all stations in the
SCU communication station network.

has been performed to characterize communication
(latency, packet loss, etc.) between remote control
segment facilities; this latency is typically under 200
msec, which easily meets the near-realtime
requirements of the PharmaSat mission.14

Internet Ground Communications Network

Control Nodes and Mission Operations Centers

Satellite command/telemetry data and communication
station configuration/status data is relayed between the
selected communication station and the designated
Mission Control Node via encrypted communications
through the public Internet, as depicted in Figure 10.
Data is streamed between distributed applications
through a suite of network bus software that includes
drivers and interfaces for the wide variety of hardware
and software components that exist within the
command and data handling architecture.

Command and telemetry operations are performed
through the use of satellite control software that allows
the operations team to remotely operate the PharmaSat.
Although the technical design of the software allows a
Control Node to operate from any location with an
Internet connection, programmatic security and
configuration control requirements have led to the
routine use of four Control Node locations: the MultiMission Operations Center (MMOC) at NASA Ames
Research Center, the SCU Robotic Control Center
located in the NASA Research Park in Moffett Field,
the SCU Satellite Operations Development and
Training laboratory on the SCU campus, and within the
SRI communication station. Some of these Control
Nodes are shown in Figures 11-13.

This data streaming architecture has been used
extensively by the SCU team in a wide variety of
realtime robotic control applications ranging from
satellite state-control to realtime piloting of remote
underwater vehicles. Significant testing of this system

Figure 12: Control Nodes at the SCU Robotic
Control Center at NASA Ames (left) and from the
SRI Communication Station (right)

Figure 10: Internet-Based Distributed Software
Architecture

Figure 11: NASA Ames MMOC
Kitts
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During launch and early orbit operations, Control Node
operations were run from the SRI station; this allowed
the entire mission operations team to work from one
location, thereby improving teamwork during this phase
of tight coupling between tracking, telemetry and
commanding operations. Within a few days, Control
Node operations migrated partially to the on-campus
SCU lab, with different combinations of the SRI or
either of the SCU S-Band communications stations
being used. Although the Ames MMOC was not used
to host realtime operations crew, the mission database
was hosted from that location, meaning that the MMOC
was in the data path for realtime contact operations for
most supports.
Figure 14: MATLAB-based Telemetry Display

The Control Nodes support a wide range of
functionality to include command formatting and
validation, telemetry processing, data archiving, and the
provision for operator graphical interfaces.
The
mission control software, designed by Santa Clara
University students, interfaces to commercial analysis
packages such as Matlab for sophisticated analyses
such as model-based anomaly management.17,18 Figure
14 shows a typical telemetry display used for routine
command verification and state of health analysis.
Orbit analysis software supports contact planning and
mission visualization. Mission data is disseminated via
the Internet for the mission team as well as for external
partners and educators.

Figure 15: PharmaSat Launch from WFF

INITIAL FLIGHT OPERATIONS

To address this, prior to the launch, the mission team
developed a range of optional, manual changes to the
pre-programmed experimental timeline.
The intent
was to exercise these options, if necessary, depending
on the health of the satellite, the health of the payload,
and the health of a new set of ground-based test
samples (that had been in stasis for the same duration as
the vehicle’s samples) that would be brought out of
stasis immediately upon launch (thereby given the team
about 2 days of advance notice regarding expected
behavior of the satellite’s samples). Complicating this
plan was the fact that the team needed to be prepared
for the case that the four-day experiment might start
execution prior to making contact with the satellite.

PharmaSat’s initial launch window was from May 5-9,
and integration of the satellite and PPOD with the
launch vehicle occurred approximately 30 days prior to
this window (biological samples had been loaded a
week prior to integration). Access to the vehicle and
the biological payload was not possible after this point
in time.
The fact that the launch occurred two weeks past the
initial launch window meant that the biological samples
had been in stasis for approximately 75% longer than
the nominal four-week duration. A ground test unit that
had been loaded with biology at the same time as the
flight card was being sampled each week after launch in
order to gauge the effect of the launch delay. Although
testing during the mission’s development phase had
never assessed biological viability past 6 weeks, results
from the ground test plate suggested that the biology
was doing well even into the 7th week of stasis.
Nevertheless, the level of uncertainty was such that the
mission team wanted to be prepared for any altered
behavior of the specimens; specifically, loss of viability
had been shown to occur in a precipitous manner once
initiated.
Kitts

Several optional changes to the pre-programmed
experiment were part of this manual command plan:
1. Allowing the experiment to start early so as to
reduce time in stasis,
2. Extending the biological specimen’s “recover
phase” (the time from activating the samples until
the antifungal was injected) in order to provide
extra time to accommodate slower-than-normal
recovery due to extended stasis,
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3.

4.

and 4 were selected for implementation as a
conservative policy.

Extending the experiment duration (by maintaining
the experiment payload temperature and continuing
data collection) to address the possibility that
biological processes may be slower than normal,
and
Lowering the transceiver duty cycle to conserve
power during the experiment given the potential for
extended experimental processing, as described in
the previous bullets.

Days 3-6: Biological Experiment
During the third day of operations, at a mission time of
approximately 47 hours after launch, a manual
command plan was executed during the day’s first
contact in order to permit the experiment to start early
(this would have been permitted automatically at the 48
hour mission time mark). During the day’s second
contact, the experiment was observed to be in the
recovery phase, as expected. During this and the third
contact of the day, the operations team lowered the
transceiver duty cycle, as planned, in order to conserve
power throughout the experiment. Status data collected
during the day showed continuing health of the vehicle,
specifically in its power profile and its ability to
maintain payload life support temperature. In addition,
initial experimental data was downloaded.

This multi-option command plan and all decision
criteria were established, verified using a hardware
flight simulator, approved by the Mission Management
Team, and used for delta training of the operations crew
prior to the new launch window.
Days 1-2: Launch & Early Orbit Check-out
On May 19, 2009, PharmaSat was successfully
launched as a secondary payload on a Minotaur launch
vehicle from Wallops Flight Facility. The launch,
shown in Figure 15, placed the satellite into its expected
orbit, which was approximately a 40° inclined circular
orbit with a 460 km altitude.

During the fourth day of operations, the final manual
adjustment to the experimental plan was implemented,
that of extending the overall biological data collection
period. In addition, continuing health of the vehicle
was verified, and experimental data was retrieved.

After launch, mission operations proceeded rapidly.
The PPOD ejected PharmaSat nominally at
approximately 22 minutes after launch, after the
primary spacecraft, TacSat-3, had been ejected, but
prior to the deployment of three additional CubeSats.

During days five, six and seven, the satellite continued
to operate in a healthy manner, and the operations team
completed retrieving all baseline experimental data.
This was verified over the course of the following two
days, with the science team ensuring that the entire
growth curve for all biological samples had been
captured and subsequently declaring that enough data
had been collected to allow successful.

During the first possible contact opportunity,
approximately 90 minutes after launch, PharmaSat
beacon packets were received with a strong signal
strength that allowed the signal to be both audibly heard
and decoded. Immediately following this contact,
beacon packets from external amateur radio operators
and universities began to be submitted to the beacon
packet submission service. On the second contact
opportunity, several S-Band commanded telemetry
download packets were successfully received; this
exceeded the expectations of the operations team and
improved the S-Band benchmark set by the GeneSat-1
mission, which didn’t establish successful S-Band
communication until the second day of operations.

Performance Examples
Table 1 summarizes the primary operational milestones
for PharmaSat, from launch through the completion of
the primary biological mission.
Table 1: Primary Operational Milestones
May 19, 2009
1655 PDT
May 19, 2009
1722 PDT
May 19, 2009
1822 PDT
May 19, 2009
2000 PDT
May 21, 2009
1600 PDT
May 25, 2009
1805 PDT
May 25, 2009
1830 PDT

During the 2nd day of operations, both S-Band and
beacon communications improved, and telemetry
analysis indicated a healthy bus and a rapidly
stabilizing spacecraft capable of supporting the powerdemanding microgravity experiment. Data was so
good, in fact, that by the 3rd day of operations, the
satellite was stable enough to initiate the experiment,
and all decision criteria regarding manual intervention
in the experimental timeline had been determined:
although biological health was positive, options 1, 3
Kitts

8

Successful Minotaur launch from WFF
Deployment of PharmaSat from P-POD
Beacon first received
2.4 GHz command & telemetry
communications established
PharmaSat
biological
experiment
initiated
96-hour biological experiment complete
and baseline data retrieved
Baseline science data disseminated to
complete mission team
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Biological results are not available at the date of this
paper, given very recent completion of the primary
experiment and the fact that, as a PI-driven science
mission, the release of experimental data is based on
NASA policy.
It is possible, however, to review key health and status
telemetry to gauge initial performance of the spacecraft.
For example, Figure 16 shows the temperature of the
payload card. The dramatic rise of temperature
occurred as expected at the start of the experiment,
when the mean card temperature was being controlled
to a set point of 27 °C. Payload heaters were being
duty cycled at an average of about 45% in order to
maintain the card temperature at this level.
Another important performance characterization
involved the evaluation of the Microhard MHX-2400
2.4 GHz communications transceiver, a COTS
component that was used with no modification for
space flight. The continued use of this component,
which was used for GeneSat-1, provided many benefits
for the spacecraft design to include a heritage pedigree,
ISM-band operation, cost, compact size, configuration
flexibility, output power, data encoding and encryption,
etc. Its continued use, however, perpetuated many
concerns regarding its performance in the space
environment, the relatively low effective command rate
experienced during the GeneSat-1 mission,16,19 and the
dependence on a high gain ground antenna.

Figure 16: Payload Temperature Profile
Table 2: Effective Communications Performance
During Week 1 of Operation
Day
Command Response Rate
1
0.6 %
2
25 %
3
32 %
4
37 %
5
45.8 %
6
44.5 %
7
63.3 %

Performance assessment of this component is especially
critical since a new version of this transceiver is being
planned for follow-on nanosatellite flights in 2010. The
command response success rate (the percentage of
transmitted commands producing a received telemetry
response) during the first week of operation is
summarized in Table 2. As expected, performance
improved as the mission progressed, largely due to
improved orbit estimates. As low as the performance
summarized in Table 2 appears, it was dramatically
better than that experienced during the first week for
GeneSat-1.

Another issue regarding the transceiver is its effective
data rate. While the transceiver broadcasts at a rate of
83 kbps, its effective throughput is dramatically lower
in practice. Indeed, during the first week of contacts,
the effective data rate was consistently less than 1 kbps.
This is due to variety of implementation issues to
include a CPU communication rate of 9600 bps, manual
execution of commands, and an intermittent link
(attributed to variable satellite antenna pointing due to
spacecraft rotation and passive magnet pointing).

It is worth noting that the command response success
rate is a round-trip measure. It is believed, and
significant evidence supports the hypothesis, that rather
than simply having cases of no command reception, it is
quite possible for a command to be successfully
received and executed and for the telemetry response to
simply be missed. For example, during the first contact
opportunity on Day 1, no telemetry responses were
received for the 223 commands that were sent;
however, the vehicle’s command count showed that 43
commands had been received and executed.

As with GeneSat-1, the fundamental use of the Internet
for realtime command and telemetry operations
influenced the nature of the general dissemination of
mission operations data. An on-line contact log was
typically filled out in near-realtime. Detailed telemetry
analyses relating to the results of contact procedures
were automatically generated via Matlab at the
conclusion of each pass and posted to an on-line data
products directory, providing mission scientists and
engineers access to the spectrum of data products –
from raw telemetry to high-level performance analyses
– within minutes of the conclusion of each contact.

Kitts
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used in project management and systems engineering,
the wide-ranging nature of different lifecycle phases,
and the real-world challenges of accomplishing a
challenging task with constrained resources.
In
addition to providing hands-on activities in university
design courses, student members of the mission
operations team were trained and certified as part of a
satellite operations course.
Furthermore, student
involvement also resulted in several undergraduate
senior design thesis projects, a Masters thesis in
advanced health management techniques, and several
design and research papers that have been widely
published and presented in peer-reviewed venues.
The involvement of the amateur radio community also
proved to be quite popular given the availability of the
beacon transmissions and the data necessary to decode
telemetry and analyze satellite performance. In the first
two weeks of the mission, amateur radio operators in
six different countries collected more than 1,000
packets of beacon telemetry. These were submitted to
the PharmaSat beacon packet submission web site
which had been created by students at Ohlone College,
CA. This doubled the amount of beacon data available
to the public compared to the baseline beacon data
collected by Santa Clara University students. Operators
submitting data received a web-based QSL card with art
based on submissions by K-5 students in northern CA.
The beacon web site allows searchable data archives to
be generated, and is expected to be a significant
element of the program’s education and public outreach
initiatives in the years to come.
Figure 17: The Web-based Mission Dashboard
Post-pass logging also included updates to a web-based
“mission dashboard,” shown in Figure 17, which
summarized mission progress, satellite health, and
science results. This page proved to be enormously
popular, resulting in more than 93,000 hits during the
first week of the mission.
Education and Outreach
The PharmaSat management team demonstrated a
compelling interest in providing an exciting and
meaningful education and outreach program as part of
the mission. Perhaps the most educationally beneficial
aspect of this program was the integral involvement in
dozens of students in the design, development, test and
operation of the spacecraft, its launch ejector, and the
ground-based command and control system. These
students ranged from freshman to Ph.D. candidates, and
they were directly exposed to – and often responsible
for - a wide range of emerging technologies, the
interdisciplinary nature of engineering, the processes
Kitts

THE MISSION TEAM
The core of the PharmaSat mission team consists of the
Principal Investigators at the University of Texas
Medical Branch, a core team of staff scientists,
engineers, and contractors within the NASA Ames
Research Center’s Small Spacecraft Office, and faculty,
staff and students in Santa Clara University’s Robotic
Systems Laboratory. Many of the individuals on the
team from Ames and Santa Clara had been key team
members for the group’s previous nanosatellites,
GeneSat-1, PreSat and NanoSail-D.
The team also worked closely with faculty, staff and
students from California Polytechnic State University
(CalPoly) at San Luis Obispo in order to coordinate the
use of the P-POD launch ejection system.
Overall, the integrated mission team demonstrated a
complementary blend of expertise capable of meeting
the unique challenges of bringing the PharmaSat
mission to flight.
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SUMMARY AND CONCLUSIONS
Launched in May 2009, the PharmaSat mission
successfully completed its primary biological
experiment within its first week of operation.
Operations during the first week of the mission have
provided valuable experimental data regarding drug
efficacy in microgravity, a key concern for the future of
human spaceflight. In addition, the performance of a
variety of advanced in situ bio-analytical technologies
has been verified, thereby contributing to the
advancement of this technology and its applicability to
small spacecraft missions. Furthermore, the mission
continues NASA Ames’ involvement in the
development of low-cost small spacecraft capable of
supporting peer-reviewed science and being developed
using industry-standard norms for project management
and systems engineering. Finally, NASA’s partnership
with regional academic institutions promotes a critical
flow of expertise to the future generation of aerospace
engineers and scientists.
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